Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET known ✓ | P07949 | 1/20 | 0.41 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.41 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.41 |
| ▸ | MAPK14 known ✓ | Q16539 | 1/20 | 0.41 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.38 |
| ▸ | TTR known ✓ | P02766 | 1/20 | 0.35 |
| ▸ | HTR1D known ✓ | P28221 | 2/20 | 0.35 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.33 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888409 | 0.98 | CYP2C19 (0.46) | CYP2C19CHEK1DAPK3RETPDGFRB | |
| Bromide SCHEMBL11681378 | 0.96 | CYP2C19 (0.44) | CYP2C19CHEK1DAPK3RETPDGFRB | |
| Sulfuric Acid SCHEMBL11682511 | 0.90 | CYP2C19 (0.40) | CYP2C19CHEK1DAPK3RETPDGFRB | |
| Phosphoric Acid SCHEMBL11680419 | 0.90 | CYP2C19 (0.40) | CYP2C19CHEK1DAPK3RETPDGFRB | |
| SCHEMBL11681060 | 0.89 | CYP2C19 (0.39) | CYP2C19CHEK1DAPK3RETPDGFRB | |
| Hydrochloric Acid SCHEMBL11679134 | 0.85 | CHEK1 (0.38) | CYP2C19CHEK1DAPK3RETPDGFRB | |
| SCHEMBL11677802 | 0.83 | CHEK1 (0.39) | CYP2C19CHEK1DAPK3RETPDGFRB | |
| SCHEMBL6330116 | 0.83 | CYP2C19 (0.35) | CYP2C19CHEK1DAPK3RETPDGFRB | |
| Water SCHEMBL11678953 | 0.82 | CYP2C19 (0.34) | CYP2C19CHEK1DAPK3RETPDGFRB | |
| SCHEMBL7930120 | 0.80 | CHEK1 (0.56) | CYP2C19CHEK1DAPK3RETPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090220516-A1 | Neuroprotection of retinal ganglion cells | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2009-09-03 | — | — | US | claimed |
| WO-2007002139-A2 | NEUROPROTECTION OF RETINAL GANGLION CELLS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2007-01-04 | — | — | WO | claimed |
| EP-0786994-B1 | USE OF CHLORIDE CHANNEL BLOCKERS FOR REDUCING INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2004-11-03 | — | — | EP | claimed |
| US-5705530-A | SIDE EFFECT REDUCTION; GLAUCOMA TREATMENT | ALLERGAN (US) | 1998-01-06 | — | — | US | claimed |
| EP-0786994-A2 | USE OF CHLORIDE CHANNEL BLOCKERS FOR REDUCING INTRAOCULAR PRESSURE | Allergan (US) | 1997-08-06 | — | — | EP | claimed |
| US-5559151-A | Method for reducing intraocular pressure in the mammalian eye by administration of chloride channel blockers | ALLERGAN (US) | 1996-09-24 | — | — | US | claimed |
| WO-1996016647-A2 | USE OF CHLORIDE CHANNEL BLOCKERS FOR REDUCING INTRAOCULAR PRESSURE | ALLERGAN (US) | 1996-06-06 | — | — | WO | claimed |
| US-4029816-A | ANTIHYPERTENSIVE, DIURETIC, SALURETIC | MERCK & CO., INC. (US) | 1977-06-14 | — | — | US | claimed |
| US-20140322193-A1 | Therapies for Disorders of the Cornea and Conjunctiva | KALEKO MICHAEL (US) | 2014-10-30 | — | — | US | disclosed |
| WO-2013082565-A1 | THERAPIES FOR DISORDERS OF THE CORNEA AND CONJUNCTIVA | KALEKO MICHAEL (US) | 2013-06-06 | — | — | WO | disclosed |
| US-20090220516-A1 | Neuroprotection of retinal ganglion cells | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2009-09-03 | — | — | US | disclosed |
| WO-2007002139-A2 | NEUROPROTECTION OF RETINAL GANGLION CELLS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-0786994-B1 | USE OF CHLORIDE CHANNEL BLOCKERS FOR REDUCING INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2004-11-03 | — | — | EP | disclosed |
| US-5866605-A | Method for providing a neuroprotective effect to the mammalian eye by administration of chloride channel blockers | ALLERGAN (US) | 1999-02-02 | — | — | US | disclosed |
| US-4709095-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, DIURETICS AND HYPOTENSIVE AGENTS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1987-11-24 | — | — | US | disclosed |
| EP-0191108-A1 | O-AMINOMETHYLPHENOL COMPOUNDS | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1986-08-20 | — | — | EP | disclosed |
| EP-0011654-A1 | Nuclear substituted 2-hydroxymethane-sulfamic acids and pharmaceutical compositions | MERCK & CO. INC. (US) | 1980-06-11 | — | — | EP | disclosed |
| US-4159279-A | SALURETIC-DIURETICS, DERMATOLOGICAL DISORDERS, ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. (US) | 1979-06-26 | — | — | US | disclosed |
| US-4156005-A | ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. (US) | 1979-05-22 | — | — | US | disclosed |
| US-4029816-A | ANTIHYPERTENSIVE, DIURETIC, SALURETIC | MERCK & CO., INC. (US) | 1977-06-14 | — | — | US | disclosed |